Opinion|Videos|January 16, 2026
Ways Oral SERDs and Targeted Therapies Could Continue to Reshape ER+ Breast Cancer Management
Author(s)Hope S. Rugo, MD, FASCO, Seth Wander, MD, PhD
Experts discuss the implications of the SERENA-6 trial, highlighting the potential benefits of early oral SERD deployment in breast cancer treatment.
Advertisement
Episodes in this series
Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss how oral SERDs and emerging targeted therapies may continue to reshape estrogen receptor–positive breast cancer management. They explore combination strategies and evolving mechanisms of resistance. Rugo and Wander consider how these advances may influence future standards of care.
Advertisement
Related to this article
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Advertisement
Advertisement
Trending on OncLive
1
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
2
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
3
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5